Saturn Clinical Trial
Are you eligible to
participate? Answer these questions to find out.
more info
Are you eligible to
participate? Answer these questions to find out.
more info
Is there a clinical trial
location near me? Find a participating location
using our Clinical Trial Locator.
search now
Read more about the
Phase 2 survival results in the
Journal of Clinical Oncology
more info
Learn more about the AFFINITY
Clinical Trial objectives and
eligibility criteria.
more info
Have any questions? Call 1-866-222-2440 to speak
with a Clinical Trial Specialist.
You can also request a call
from a Clinical Trial Specialist.
request a call
Know someone who might be interested
in the Prostate Cancer AFFINITY Clinical
Trial? Print this Fact Sheet to share with
a family member or friend.
download

Are you eligible to participate?

Answer these questions to find out.

more info

Know someone who might be interested
in the Prostate Cancer AFFINITY Clinical Trial? Print this Fact Sheet to share with a family member or friend.

download

Is there a clinical trial location near me?

Find a participating location using our Clincal Trial Locator.

search now

Have any questions?
Call 1-866-222-2440 to speak with a Clinical Trial Specialist. You can also request a call from a Clinical Trial Specialist.

request a call

About the Prostate Cancer
AFFINITY Clinical Trial

The goal of this Phase 3 clinical trial is to test whether adding an experimental drug called custirsen to Jevtana® (cabazitaxel) chemotherapy can help treat metastatic castrate-resistant prostate cancer (CRPC).

Read More +

Disclaimer: Custirsen (OGX-011) is not approved for commercial use in the United States or in countries outside of the United States. Custirsen is an investigational new drug that is being studied for the treatment of prostate cancer in clinical trials.

Taxotere® and Jevtana® are registered trademarks of Sanofi-aventis.

Taxotere® and Jevtana® are registered trademarks of Sanofi-aventis.

Taxotere® is a registered trademark of Sanofi-aventis.

Tylenol® #3 with codeine is a registered trademark of McNeil Consumer Healthcare.

*Most prostate cancer initially responds to various therapies, but eventually becomes resistant and often spreads to other parts of the body.

You are now leaving www.ProstateCancerStudy.com.

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. We encourage you to read the privacy policy of every website
you visit.

Click "Continue" to proceed or "Return" to return to ProstateCancerStudy.com.

Continue Return

Your browser is out of date. For the best experience using this website, please upgrade your web browser.

Close
Close

Request a call

If you have any questions about the Prostate Cancer AFFINITY Clinical Trial, please complete this form to request a call from a Clinical Trial Specialist.

Please provide information for the highlighted fields below.

An error occurred while processing this form. Please try resubmitting later.

Your first name
Your last name
Your phone number
Best times to call you
The call center is open from 5 am to 5 pm PST.
Your time zone
-->